F. Fujiki

发表

CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients

M. Hino, S. Kishida, N. Hosen, 2012, Leukemia.

A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches

Z. Berneman, H. Sugiyama, Q. Lecocq, 2018, Oncotarget.

The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers

T. Yoshimine, E. Morii, H. Inohara, 2014, International journal of oncology.

Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle.

Y. Doki, M. Mori, K. Aozasa, 2009, International journal of oncology.

Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study

H. Eguchi, H. Nagano, M. Unno, 2018, Cancer Immunology Research.

Immune adjuvant therapy using Bacillus Calmette–Guérin cell wall skeleton (BCG-CWS) in advanced malignancies

I. Kawase, S. Morita, Toshinori Ito, 2019, Medicine.

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.

T. Kyo, H. Dohy, I. Kawase, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Regeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes

N. Kadowaki, H. Sugiyama, T. Maeda, 2020, Molecular therapy. Methods & clinical development.

Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides

N. Hosen, Y. Oji, A. Tsuboi, 2020, Cancer Immunology, Immunotherapy.

An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells

N. Hosen, Y. Oji, A. Tsuboi, 2016, Journal of immunotherapy.

Identification of a WT1 protein‐derived peptide, WT1187, as a HLA‐A*0206‐restricted, WT1‐specific CTL epitope

I. Kawase, N. Hosen, Y. Oji, 2008, Microbiology and immunology.

T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy

M. Ikawa, N. Hosen, Y. Oji, 2021, bioRxiv.

Identification and Characterization of a WT1 (Wilms Tumor Gene) Protein-derived HLA-DRB1*0405-restricted 16-mer Helper Peptide That Promotes the Induction and Activation of WT1-specific Cytotoxic T Lymphocytes

I. Kawase, Y. Oji, M. Kawakami, 2007, Journal of immunotherapy.

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.

H. Goossens, G. Juliusson, K. Ladell, 2017, Blood.

Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms

N. Hosen, Y. Oji, A. Tsuboi, 2015, PloS one.

A WT1 protein‐derived, naturally processed 16‐mer peptide, WT1332, is a promiscuous helper peptide for induction of WT1‐specific Th1‐type CD4+ T cells

I. Kawase, Y. Oji, A. Tsuboi, 2008, Microbiology and immunology.

Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis

N. Hosen, Y. Oji, A. Tsuboi, 2016, PloS one.

WT1 Peptide Vaccine for the Treatment of Malignancies: Its Development, Recent Progress, and Future Perspectives

N. Hosen, Y. Oji, A. Tsuboi, 2016 .

Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing

H. Goossens, Z. Berneman, H. Sugiyama, 2018, Front. Immunol..

Biased usage of T cell receptor β‐chain variable region genes of Wilms’ tumor gene (WT1)‐specific CD8+ T cells in patients with solid tumors and healthy donors

T. Yoshimine, T. Enomoto, M. Sekimoto, 2012, Cancer Science.

Functional human Th17 clones with WT1-specific helper activity

N. Hosen, Y. Oji, A. Tsuboi, 2013, Cancer Immunology, Immunotherapy.

A Zbtb7a proto‐oncogene as a novel target for miR‐125a

N. Hosen, Y. Oji, A. Tsuboi, 2016, Molecular carcinogenesis.

WT1 peptide‐based immunotherapy for advanced thymic epithelial malignancies

J. Sakamoto, E. Morii, S. Morita, 2018, International journal of cancer.

Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies

I. Kawase, N. Hosen, Y. Oji, 2005, Leukemia.

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia

K. Takeda, T. Shirakawa, A. Tsuboi, 2022, Cancer Immunology, Immunotherapy.

Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides

N. Hosen, Y. Oji, A. Tsuboi, 2018, Oncotarget.

HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T Lymphocytes Display a Helper Activity for WT1-specific CTL Induction and a Cytotoxicity Against Leukemia Cells

N. Hosen, Y. Oji, A. Tsuboi, 2013, Journal of immunotherapy.

Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.

N. Hosen, Y. Oji, A. Tsuboi, 2012, Anticancer research.

Recognition of a Natural WT 1 Epitope by a Modified WT 1 Peptide-specific T-Cell Receptor

N. Hosen, Y. Oji, A. Tsuboi, 2012 .

Enhancement of Efficacy of Wilms’ Tumor Gene WT1 Product-derived Peptide Cancer Vaccine by Co-administration with Immunopotentiating Agents: Lessons from Mouse Models

N. Hosen, Y. Oji, A. Tsuboi, 2015 .

Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.

I. Kawase, N. Hosen, Y. Oji, 2012, Vaccine.

Establishment of HLA-DR4 Transgenic Mice for the Identification of CD4+ T Cell Epitopes of Tumor-Associated Antigens

S. Senju, Y. Nishimura, H. Sugiyama, 2013, PloS one.

WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone

I. Kawase, K. Aozasa, Y. Oji, 2004, Cancer Immunology, Immunotherapy.

A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma

J. Sakamoto, S. Morita, N. Hosen, 2018, Cancer Immunology, Immunotherapy.

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide

T. Yoshimine, J. Sakamoto, S. Morita, 2016, International journal of cancer.

Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain

K. Akashi, K. Takenaka, H. Kishima, 2022, Science Translational Medicine.

The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR T cell therapy

T. Nakao, J. Takagi, K. Takeda, 2017, Nature Medicine.

WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1

H. Kishima, M. Ohmi, N. Naka, 2023, Cancers.

Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities

E. Morii, N. Hosen, Y. Oji, 2016, Oncogene.

Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia

T. Shirakawa, A. Tsuboi, K. Ozono, 2023, BMC Cancer.

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia

K. Takeda, T. Shirakawa, A. Tsuboi, 2022, Cancer Immunology, Immunotherapy.

Identification of mouse helper epitopes for WT1-specific CD4+ T cells

N. Hosen, Y. Oji, A. Tsuboi, 2021, Cancer Immunology, Immunotherapy.

Imaging Assessment of Tumor Response in the Era of Immunotherapy

J. Hatazawa, Y. Oji, A. Tsuboi, 2021, Diagnostics.

Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine

K. Mizuguchi, N. Hosen, Y. Oji, 2016, Future science OA.

Two distinct effector memory cell populations of WT1 (Wilms’ tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients

Kenji Mizuguchi, Sumiyuki Nishida, Atsushi Kumanogoh, 2015, Cancer Immunology, Immunotherapy.

WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.

I. Kawase, N. Hosen, Y. Oji, 2009, Anti-cancer agents in medicinal chemistry.

Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.

N. Hosen, Y. Oji, A. Tsuboi, 2015, Anticancer research.

In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity

N. Hosen, Y. Oji, A. Tsuboi, 2014, Leukemia.

High frequencies of less differentiated and more proliferative WT1‐specific CD8+ T cells in bone marrow in tumor‐bearing patients: An important role of bone marrow as a secondary lymphoid organ

I. Kawase, T. Enomoto, T. Ueda, 2010, Cancer science.

A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination.

Y. Takeda, T. Yoshimine, I. Kawase, 2010, Anticancer research.

Biased usage of BV gene families of T‐cell receptors of WT1 (Wilms’ tumor gene)‐specific CD8+ T cells in patients with myeloid malignancies

Y. Kanda, I. Kawase, N. Hosen, 2010, Cancer science.

WT1 Peptide Cancer Vaccine for Patients with Hematopoietic Malignancies and Solid Cancers

I. Kawase, N. Hosen, Y. Oji, 2007, TheScientificWorldJournal.

Wilms tumour 1 peptide vaccine as a cure‐oriented post‐chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse

N. Hosen, Y. Oji, M. Kawakami, 2018, British journal of haematology.

An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells

N. Hosen, Y. Oji, A. Tsuboi, 2015, PloS one.

Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine

M. Hino, N. Hosen, Y. Oji, 2013, Blood Cancer Journal.

"Cancer antigen WT1 protein-derived peptide"-based treatment of cancer -toward the further development.

I. Kawase, N. Hosen, Y. Oji, 2008, Current medicinal chemistry.

WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine

E. Morii, N. Naka, N. Hosen, 2022, Oncology letters.

Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer

T. Enomoto, S. Morita, N. Hosen, 2021, Journal of immunotherapy.

Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.

J. Sakamoto, A. Ogata, I. Kawase, 2007, International journal of hematology.

Wilms Tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma

J. Sakamoto, A. Ogata, I. Kawase, 2007, International journal of hematology.

Identification of a Wilms’ tumor 1-derived immunogenic CD4+ T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes

Z. Berneman, Y. Oji, H. Sugiyama, 2013, Leukemia.

Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs

Y. Oji, A. Tsuboi, Y. Oka, 2023, Cancer Immunology, Immunotherapy.

Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity

Y. Nishida, N. Hosen, Y. Oji, 2018, Oncotarget.

WT1235, a Ninemer Peptide Derived from Wilms’ Tumor Gene Product, Is a Candidate Peptide for the Vaccination of HLA-A*0201-Positive Patients with Hematopoietic Malignancies

I. Kawase, Y. Oji, M. Kawakami, 2005, International journal of hematology.